Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from VISEN Pharmaceuticals ( (HK:2561) ).
VISEN Pharmaceuticals has called an extraordinary general meeting in Shanghai on April 22, 2026, asking shareholders to approve an Exclusive Licence Framework Agreement with certain Ascendis subsidiaries, including revised 2026 and future annual caps for these connected transactions. The board is also seeking approval for a first Commercial Supply Framework Agreement with Ascendis Pharma Endocrinology Division and a supplemental agreement to a second Commercial Supply Framework Agreement with Ascendis Europe, moves that formalize and expand long-term supply and licensing arrangements and underline VISEN’s reliance on Ascendis as a strategic partner for product supply and commercialization.
All resolutions at the EGM will be voted on by poll, with shareholders able to appoint proxies and required to meet specified deadlines for proxy submission and share transfer registration. The company has also set contingency arrangements and communication plans for potential severe weather disruptions on the meeting date, reflecting regulatory compliance and operational discipline important to minority investors and Hong Kong market stakeholders.
The most recent analyst rating on (HK:2561) stock is a Hold with a HK$38.00 price target. To see the full list of analyst forecasts on VISEN Pharmaceuticals stock, see the HK:2561 Stock Forecast page.
More about VISEN Pharmaceuticals
VISEN Pharmaceuticals, incorporated in the Cayman Islands and listed in Hong Kong, operates in the biopharmaceutical sector with a focus on endocrinology-related products. The company works closely with Ascendis group entities, using licensing and commercial supply arrangements to support the development and commercialization of its therapies in China and other markets.
Average Trading Volume: 23,705
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$3.02B
For an in-depth examination of 2561 stock, go to TipRanks’ Overview page.